Title: The Effectiveness Observation of Recombinant Human Thrombopoietin Treatment for Chronic Immune Thrombocytopenia Clinical Observation
Abstract: Objective Evaluate the clinical effectiveness and safety of recombinant human thrombopoietin(rhTPO) treatment for chronic immune thrombocytopenia.Methods Give rhTPO 1.0 μg/kg subcutaneous injection to patients with chronic ITP,1 time/d,last for a week,and then change to 3 times/week,one month later change to 2 times/week,one more month later change to 1 time/week.Results 15 patients' median of platelet count before drug was 16.9(6.0~30.0)×109/L,Drug use up 5 days,7 days,15 days were up by to 40.0(16.0~56.0)×109/L、94.7(50~140.0)×109/L and 115.7(70.0~165.0)×109/L,compared with before treatment(P0.01).After discontinuation,platelet count gradually fell back,till the 30th day,the median of platelet count fell back to 83.2(60.0~96.0)×109/L,still obviously higher than before treatment(P 0.01).Recently effective rate is 100%.Among them,the obvious effects of 73.3%(platelet≥100×109/L,no bleeding symptoms),the well effects of 26.7%(platelet count up to 50×109/L,or 30×109/L higher the original,or basically no bleeding symptoms).Only 2 patients had mild clinical adverse reaction.Conclusion rhTPO can increase the platelet count of patients with chronic ITP one-time,curative effect is distinct,also with a long time maintaining and a mild adverse reactions.
Publication Year: 2012
Publication Date: 2012-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot